Skip to main content
Erschienen in: Herz 5/2023

20.04.2023 | Original articles

Relationship between myocardial bridging and fatal ventricular arrhythmias in patients with hypertrophic cardiomyopathy: the HCM-MB study

verfasst von: Ahmet Güner, MD, Sezgin Atmaca, MD, İsmail Balaban, MD, İrem Türkmen, MD, Doğancan Çeneli, MD, Aysel Türkvatan, MD, Ender Öner, MD, Özgür Sürgit, MD, Arda Güler, MD, Fatih Uzun, MD, Gamze Babür Güler, MD, Serkan Kahraman, MD, Selçuk Pala, MD, Nuri Havan, MD, Mustafa Yıldız, MD, Mehmet Ertürk, MD

Erschienen in: Herz | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Myocardial bridging (MB) and hypertrophic cardiomyopathy (HCM) are associated with the risk of fatal ventricular arrhythmias (VAs). The goal of the study was to determine the relationship between MB and fatal VAs in HCM patients with implantable cardiac defibrillators (ICD).

Methods

A total of 108 HCM patients (mean age: 46.6 ± 13.6 years; male: 73) were enrolled in this retrospective study. All patients underwent transthoracic echocardiography and coronary computed tomography angiography. Fatal VAs including sustained ventricular tachycardia and ventricular fibrillation were documented in ICD records.

Results

There were documented fatal VAs in 29 (26.8%) patients during a mean follow-up time of 71.3 ± 30.9 months. Compared with the other groups, the fatal VA group had a higher incidence of the following: presence of MB (82.8 vs. 38%, p < 0.001), deep MB (62.1 vs. 6.3%, p < 0.001), very deep MB (24.1 vs. 0%, p < 0.001), long MB (65.5 vs. 11.4%, p < 0.001), presence of > 1 MB (17.2 vs. 0%, p = 0.001), and MB of the left anterior descending artery (79.3 vs. 17.7%, p < 0.001) . Sudden cardiac death (SCD) risk score (hazard ratio: 1.194; 95% CI: 1.071–1.330; p = 0.001) and presence of MB (hazard ratio: 3.815; 95% CI: 1.41–10.284; p = 0.008) were found to be independent predictors of fatal VAs in HCM patients.

Conclusions

The current data suggest that the SCD risk score and presence of MB were independent risk factors for fatal VAs in patients with HCM. In addition to conventional risk factors, the coronary anatomical course can provide clinicians with valuable information when assessing the risk of fatal VAs in HCM patients.
Literatur
1.
Zurück zum Zitat Sternheim D, Power DA, Samtani R et al (2021) Myocardial bridging: diagnosis, functional assessment, and management: JACC state-of-the-art review. J Am Coll Cardiol 78:2196–2212CrossRefPubMed Sternheim D, Power DA, Samtani R et al (2021) Myocardial bridging: diagnosis, functional assessment, and management: JACC state-of-the-art review. J Am Coll Cardiol 78:2196–2212CrossRefPubMed
2.
Zurück zum Zitat Olivotto I, Cecchi F, Yacoub MH (2009) Myocardial bridging and sudden death in hypertrophic cardiomyopathy: salome drops another veil. Eur Heart J 30:1549–1550CrossRefPubMed Olivotto I, Cecchi F, Yacoub MH (2009) Myocardial bridging and sudden death in hypertrophic cardiomyopathy: salome drops another veil. Eur Heart J 30:1549–1550CrossRefPubMed
3.
Zurück zum Zitat Gori F, Basso C, Thiene G (2000) Myocardial infarction in a patient with hypertrophic cardiomyopathy. N Engl J Med 342:593–594CrossRefPubMed Gori F, Basso C, Thiene G (2000) Myocardial infarction in a patient with hypertrophic cardiomyopathy. N Engl J Med 342:593–594CrossRefPubMed
4.
Zurück zum Zitat Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R (1998) Myocardial bridging in children with hypertrophic cardiomyopath—a risk factor for sudden death. N Engl J Med 339:1201–1209CrossRefPubMed Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R (1998) Myocardial bridging in children with hypertrophic cardiomyopath—a risk factor for sudden death. N Engl J Med 339:1201–1209CrossRefPubMed
5.
Zurück zum Zitat Nie C, Zhu C, Yang Q, Xiao M, Meng Y, Wang S (2021) Myocardial bridging of the left anterior descending coronary artery as a risk factor for atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy: a matched case-control study. BMC Cardiovasc Disord 21:382CrossRefPubMedPubMedCentral Nie C, Zhu C, Yang Q, Xiao M, Meng Y, Wang S (2021) Myocardial bridging of the left anterior descending coronary artery as a risk factor for atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy: a matched case-control study. BMC Cardiovasc Disord 21:382CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMed Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMed
7.
Zurück zum Zitat van der Velde N, Huurman R, Yamasaki Y et al (2020) Frequency and significance of coronary artery disease and myocardial bridging in patients with hypertrophic cardiomyopathy. Am J Cardiol 125:1404–1412CrossRefPubMed van der Velde N, Huurman R, Yamasaki Y et al (2020) Frequency and significance of coronary artery disease and myocardial bridging in patients with hypertrophic cardiomyopathy. Am J Cardiol 125:1404–1412CrossRefPubMed
8.
9.
Zurück zum Zitat Konen E, Goitein O, Sternik L et al (2007) The prevalence and anatomical patterns of intramuscular coronary arteries: a coronary computed tomography angiographic study. J Am Coll Cardiol 49:587–593CrossRefPubMed Konen E, Goitein O, Sternik L et al (2007) The prevalence and anatomical patterns of intramuscular coronary arteries: a coronary computed tomography angiographic study. J Am Coll Cardiol 49:587–593CrossRefPubMed
10.
Zurück zum Zitat Leipsic J, Abbara S, Achenbach S et al (2014) SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the society of cardiovascular computed tomography guidelines committee. J Cardiovasc Comput Tomogr 8:342–358CrossRefPubMed Leipsic J, Abbara S, Achenbach S et al (2014) SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the society of cardiovascular computed tomography guidelines committee. J Cardiovasc Comput Tomogr 8:342–358CrossRefPubMed
11.
Zurück zum Zitat Geske JB, Ommen SR, Gersh BJ (2018) Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail 6:364–375CrossRefPubMed Geske JB, Ommen SR, Gersh BJ (2018) Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail 6:364–375CrossRefPubMed
12.
Zurück zum Zitat Williams B, Mancia G, Spiering W et al (2018) ESC scientific document group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104CrossRefPubMed Williams B, Mancia G, Spiering W et al (2018) ESC scientific document group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104CrossRefPubMed
13.
Zurück zum Zitat McDonagh TA, Metra M, Adamo M et al (2021) ESC scientific document group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726CrossRefPubMed McDonagh TA, Metra M, Adamo M et al (2021) ESC scientific document group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726CrossRefPubMed
14.
Zurück zum Zitat Mach F, Baigent C, Catapano AL et al (2020) ESC scientific document group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188CrossRefPubMed Mach F, Baigent C, Catapano AL et al (2020) ESC scientific document group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188CrossRefPubMed
15.
Zurück zum Zitat McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726CrossRefPubMed McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726CrossRefPubMed
16.
Zurück zum Zitat Anderson J, Glynn LG (2011) Definition of chronic kidney disease and measurement of kidney function in original research papers: a review of the literature. Nephrol Dial Transplant 26:2793–2798CrossRefPubMed Anderson J, Glynn LG (2011) Definition of chronic kidney disease and measurement of kidney function in original research papers: a review of the literature. Nephrol Dial Transplant 26:2793–2798CrossRefPubMed
17.
Zurück zum Zitat Mark DG, Huang J, Chettipally U, Kene MV, Anderson ML, Hess EP et al (2018) Performance of coronary risk scores among patients with chest pain in the emergency department. J Am Coll Cardiol 71:606–616CrossRefPubMed Mark DG, Huang J, Chettipally U, Kene MV, Anderson ML, Hess EP et al (2018) Performance of coronary risk scores among patients with chest pain in the emergency department. J Am Coll Cardiol 71:606–616CrossRefPubMed
18.
Zurück zum Zitat O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E et al (2014) Hypertrophic cardiomyopathy outcomes investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35:2010–2020CrossRefPubMed O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E et al (2014) Hypertrophic cardiomyopathy outcomes investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35:2010–2020CrossRefPubMed
19.
Zurück zum Zitat Agatston AS, Janowitz WR, Hildner FJ et al (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832CrossRefPubMed Agatston AS, Janowitz WR, Hildner FJ et al (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832CrossRefPubMed
20.
21.
Zurück zum Zitat Tower-Rader A, Kramer CM, Neubauer S, Nagueh SF, Desai MY (2020) Multimodality imaging in hypertrophic cardiomyopathy for risk stratification. Circ Cardiovasc Imaging 13:e9026CrossRefPubMedPubMedCentral Tower-Rader A, Kramer CM, Neubauer S, Nagueh SF, Desai MY (2020) Multimodality imaging in hypertrophic cardiomyopathy for risk stratification. Circ Cardiovasc Imaging 13:e9026CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Ramchand J, Fava AM, Chetrit M, Desai MY (2020) Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy. Heart 106:793–801CrossRefPubMed Ramchand J, Fava AM, Chetrit M, Desai MY (2020) Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy. Heart 106:793–801CrossRefPubMed
23.
Zurück zum Zitat Wang W, Lian Z, Rowin EJ et al (2017) Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 10:e4604CrossRefPubMed Wang W, Lian Z, Rowin EJ et al (2017) Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 10:e4604CrossRefPubMed
24.
Zurück zum Zitat Raphael CE, Cooper R, Parker KH, Collinson J, Vassiliou V, Pennell DJ et al (2016) Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. J Am Coll Cardiol 68:1651–1660CrossRefPubMedPubMedCentral Raphael CE, Cooper R, Parker KH, Collinson J, Vassiliou V, Pennell DJ et al (2016) Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. J Am Coll Cardiol 68:1651–1660CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–495CrossRefPubMed Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–495CrossRefPubMed
27.
Zurück zum Zitat Möhlenkamp S, Hort W, Ge J, Erbel R (2002) Update on myocardial bridging. Circulation 106:2616–2622CrossRefPubMed Möhlenkamp S, Hort W, Ge J, Erbel R (2002) Update on myocardial bridging. Circulation 106:2616–2622CrossRefPubMed
28.
Zurück zum Zitat Lazoura O, Kanavou T, Vassiou K, Gkiokas S, Fezoulidis IV (2010) Myocardial bridging evaluated with 128-multi detector computed tomography coronary angiography. Surg Radiol Anat 32:45–50CrossRefPubMed Lazoura O, Kanavou T, Vassiou K, Gkiokas S, Fezoulidis IV (2010) Myocardial bridging evaluated with 128-multi detector computed tomography coronary angiography. Surg Radiol Anat 32:45–50CrossRefPubMed
29.
Zurück zum Zitat Hwang JH, Ko SM, Roh HG, Song MG, Shin JK, Chee HK et al (2010) Myocardial bridging of the left anterior descending coronary artery: depiction rate and morphologic features by dual-source CT coronary angiography. Korean J Radiol 11:514–521CrossRefPubMedPubMedCentral Hwang JH, Ko SM, Roh HG, Song MG, Shin JK, Chee HK et al (2010) Myocardial bridging of the left anterior descending coronary artery: depiction rate and morphologic features by dual-source CT coronary angiography. Korean J Radiol 11:514–521CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Nishikii-Tachibana M, Pargaonkar VS, Schnittger I et al (2018) Myocardial bridging is associated with exercise-induced ventricular arrhythmia and increases in QT dispersion. Ann Noninvasive Electrocardiol 23:e12492CrossRefPubMed Nishikii-Tachibana M, Pargaonkar VS, Schnittger I et al (2018) Myocardial bridging is associated with exercise-induced ventricular arrhythmia and increases in QT dispersion. Ann Noninvasive Electrocardiol 23:e12492CrossRefPubMed
31.
Zurück zum Zitat Cay S, Oztürk S, Cihan G, Kisacik HL, Korkmaz S (2006) Angiographic prevalence of myocardial bridging. Anadolu Kardiyol Derg 6:9–12PubMed Cay S, Oztürk S, Cihan G, Kisacik HL, Korkmaz S (2006) Angiographic prevalence of myocardial bridging. Anadolu Kardiyol Derg 6:9–12PubMed
32.
Zurück zum Zitat Murtaza G, Mukherjee D, Gharacholou SM et al (2020) An updated review on myocardial bridging. Cardiovasc Revasc Med 21:1169–1179CrossRefPubMed Murtaza G, Mukherjee D, Gharacholou SM et al (2020) An updated review on myocardial bridging. Cardiovasc Revasc Med 21:1169–1179CrossRefPubMed
33.
Zurück zum Zitat Feld H, Guadanino V, Hollander G et al (1991) Exercise-induced ventricular tachycardia in association with a myocardial bridge. Chest 99:1295–1296CrossRefPubMed Feld H, Guadanino V, Hollander G et al (1991) Exercise-induced ventricular tachycardia in association with a myocardial bridge. Chest 99:1295–1296CrossRefPubMed
34.
Zurück zum Zitat Kurath-Koller S, Sallmon H, Scherr D et al (2020) Wearable cardioverter-defibrillator as bridging to ICD in pediatric hypertrophic cardiomyopathy with myocardial bridging—a case report. BMC Pediatr 20:207CrossRefPubMedPubMedCentral Kurath-Koller S, Sallmon H, Scherr D et al (2020) Wearable cardioverter-defibrillator as bridging to ICD in pediatric hypertrophic cardiomyopathy with myocardial bridging—a case report. BMC Pediatr 20:207CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Juillière Y, Berder V, Suty-Selton C et al (1995) Isolated myocardial bridges with angiographic milking of the left anterior descending coronary artery: a long-term follow-up study. Am Heart J 129:663–665CrossRefPubMed Juillière Y, Berder V, Suty-Selton C et al (1995) Isolated myocardial bridges with angiographic milking of the left anterior descending coronary artery: a long-term follow-up study. Am Heart J 129:663–665CrossRefPubMed
36.
Zurück zum Zitat Cecchi F, Olivotto I, Gistri R et al (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349:1027–1035CrossRefPubMed Cecchi F, Olivotto I, Gistri R et al (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349:1027–1035CrossRefPubMed
37.
Zurück zum Zitat Hostiuc S, Rusu MC, Hostiuc M, Negoi RI, Negoi I (2017) Cardiovascular consequences of myocardial bridging: a meta-analysis and meta-regression. Sci Rep 7:14644CrossRefPubMedPubMedCentral Hostiuc S, Rusu MC, Hostiuc M, Negoi RI, Negoi I (2017) Cardiovascular consequences of myocardial bridging: a meta-analysis and meta-regression. Sci Rep 7:14644CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Bruce C, Ubhi N, McKeegan P, Sanders K (2023) Systematic review and meta-analysis of cardiovascular consequences of myocardial bridging in hypertrophic cardiomyopathy. Am J Cardiol 188:110–119CrossRefPubMed Bruce C, Ubhi N, McKeegan P, Sanders K (2023) Systematic review and meta-analysis of cardiovascular consequences of myocardial bridging in hypertrophic cardiomyopathy. Am J Cardiol 188:110–119CrossRefPubMed
Metadaten
Titel
Relationship between myocardial bridging and fatal ventricular arrhythmias in patients with hypertrophic cardiomyopathy: the HCM-MB study
verfasst von
Ahmet Güner, MD
Sezgin Atmaca, MD
İsmail Balaban, MD
İrem Türkmen, MD
Doğancan Çeneli, MD
Aysel Türkvatan, MD
Ender Öner, MD
Özgür Sürgit, MD
Arda Güler, MD
Fatih Uzun, MD
Gamze Babür Güler, MD
Serkan Kahraman, MD
Selçuk Pala, MD
Nuri Havan, MD
Mustafa Yıldız, MD
Mehmet Ertürk, MD
Publikationsdatum
20.04.2023
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 5/2023
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-023-05171-9

Weitere Artikel der Ausgabe 5/2023

Herz 5/2023 Zur Ausgabe

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.